These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 23294722)
1. [Expressions of EZH2 and RUNX3 in renal cell carcinoma and their clinical significance]. Wang G; Qin W; Zheng J; Wei M; Zhou X; Wang H; Wen W Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):82-4, 88. PubMed ID: 23294722 [TBL] [Abstract][Full Text] [Related]
2. Alterations in enhancer of zeste homolog 2, matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression are associated with ex vivo and in vitro bone metastasis in renal cell carcinoma. Wang J; Ren Y; Guo X; Cheng H; Ye Y; Qi J; Yang C; You H Mol Med Rep; 2015 May; 11(5):3585-92. PubMed ID: 25571919 [TBL] [Abstract][Full Text] [Related]
3. [Expression and relationship of Ezh2, Runx3 and caspase-3 in endometrial adenocarcinoma]. Guo ZL; Chen K; Wang XQ; Hu W Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):387-91. PubMed ID: 21914347 [TBL] [Abstract][Full Text] [Related]
4. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature. Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759 [TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma. Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J BJU Int; 2016 Feb; 117(2):351-62. PubMed ID: 24612432 [TBL] [Abstract][Full Text] [Related]
6. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. Chen F; Bai J; Li W; Mei P; Liu H; Li L; Pan Z; Wu Y; Zheng J PLoS One; 2013; 8(2):e56241. PubMed ID: 23457532 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas. Wang Y; Chen Y; Geng H; Qi C; Liu Y; Yue D Tumour Biol; 2015 Sep; 36(9):7159-66. PubMed ID: 25877750 [TBL] [Abstract][Full Text] [Related]
8. Expression of EZH2 in renal cell carcinoma as a novel prognostic marker. Lee HW; Choe M Pathol Int; 2012 Nov; 62(11):735-41. PubMed ID: 23121604 [TBL] [Abstract][Full Text] [Related]
9. The enhancer of zeste homolog 2 gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells. Wagener N; Holland D; Bulkescher J; Crnković-Mertens I; Hoppe-Seyler K; Zentgraf H; Pritsch M; Buse S; Pfitzenmaier J; Haferkamp A; Hohenfellner M; Hoppe-Seyler F Int J Cancer; 2008 Oct; 123(7):1545-50. PubMed ID: 18623083 [TBL] [Abstract][Full Text] [Related]
10. Expression profile of the polycomb group protein enhancer of Zeste homologue 2 and its prognostic relevance in renal cell carcinoma. Hinz S; Weikert S; Magheli A; Hoffmann M; Engers R; Miller K; Kempkensteffen C J Urol; 2009 Dec; 182(6):2920-5. PubMed ID: 19846140 [TBL] [Abstract][Full Text] [Related]
11. Long Noncoding RNA MALAT1 Promotes Aggressive Renal Cell Carcinoma through Ezh2 and Interacts with miR-205. Hirata H; Hinoda Y; Shahryari V; Deng G; Nakajima K; Tabatabai ZL; Ishii N; Dahiya R Cancer Res; 2015 Apr; 75(7):1322-31. PubMed ID: 25600645 [TBL] [Abstract][Full Text] [Related]
12. Loss of RUNX3 expression is an independent adverse prognostic factor in diffuse large B-cell lymphoma. Duncan VE; Ping Z; Varambally S; Peker D Leuk Lymphoma; 2017 Jan; 58(1):179-184. PubMed ID: 27184221 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EZH2 expression and activity in renal cell carcinoma: a prospective study. Liu L; Xu Z; Zhong L; Wang H; Jiang S; Long Q; Xu J; Guo J PLoS One; 2013; 8(11):e81484. PubMed ID: 24312307 [TBL] [Abstract][Full Text] [Related]
14. ZMYND8 preferentially binds phosphorylated EZH2 to promote a PRC2-dependent to -independent function switch in hypoxia-inducible factor-activated cancer. Tang B; Sun R; Wang D; Sheng H; Wei T; Wang L; Zhang J; Ho TH; Yang L; Wei Q; Huang H Proc Natl Acad Sci U S A; 2021 Feb; 118(8):. PubMed ID: 33593912 [TBL] [Abstract][Full Text] [Related]
15. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. Ho TH; Kapur P; Eckel-Passow JE; Christie A; Joseph RW; Serie DJ; Cheville JC; Thompson RH; Homayoun F; Panwar V; Brugarolas J; Parker AS J Clin Oncol; 2017 Nov; 35(32):3706-3713. PubMed ID: 28976794 [TBL] [Abstract][Full Text] [Related]
16. [Relationship between Expression of Runt-related Transcription Factor 3 and Enhancer of zeste Homolog 2 Proteins and Sensitivity to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer]. Yuan ZL; Wu XL; Qu M; Xue J; Han L; Sun GY Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2021 Dec; 43(6):856-864. PubMed ID: 34980322 [TBL] [Abstract][Full Text] [Related]
17. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer. Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058 [TBL] [Abstract][Full Text] [Related]
18. EZH2 promotes cell proliferation by regulating the expression of RUNX3 in laryngeal carcinoma. Lian R; Ma H; Wu Z; Zhang G; Jiao L; Miao W; Jin Q; Li R; Chen P; Shi H; Yu W Mol Cell Biochem; 2018 Feb; 439(1-2):35-43. PubMed ID: 28795320 [TBL] [Abstract][Full Text] [Related]
19. EZH2 promotes tumor progression by increasing VEGF expression in clear cell renal cell carcinoma. Xu ZQ; Zhang L; Gao BS; Wan YG; Zhang XH; Chen B; Wang YT; Sun N; Fu YW Clin Transl Oncol; 2015 Jan; 17(1):41-9. PubMed ID: 24986100 [TBL] [Abstract][Full Text] [Related]
20. [Correlation between the PTEN/MMAC1/TEP1 expression and cell proliferation and apoptosis in human renal cell carcinoma (RCC)]. Li JY; Cao RF; Wang H; Xie QX; Wang GX; Xiong LS; Miao YR Ai Zheng; 2003 Jun; 22(6):607-11. PubMed ID: 12948410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]